Want to track PCVX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 72 days
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
Vaxcyte shares rocketed Tuesday after the biotech company delivered "stunning" test results for its pneumococcal vaccine.
Investors | 1 year ago
Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine
Vaxcyte Inc.'s stock soared 33% early Tuesday, after the vaccine maker reported positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine candidate in adults aged 50 and older.
Marketwatch | 1 year ago
Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
The consensus price target hints at a 25.2% upside potential for Vaxcyte (PCVX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks | 1 year ago
Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice
Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks | 1 year ago
2025 © Marketlog. All Rights Reserved.
